Physician profile
Samer Salmo
NPI 1326277567
$1,154.34
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $161 · 2021: $52.06 · 2022: $48.01.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $240.63 | 2019 | |
| Sunovion Pharmaceuticals INC. | $224.18 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $161.43 | 2019 | |
| Lundbeck LLC | $144.31 | 2019-2020 | |
| Abbvie INC. | $100.07 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $96.01 | 2019-2020 | |
| Shire North American Group INC | $61.68 | 2019 | |
| Neurocrine Biosciences, INC. | $52.01 | 2019-2020 | |
| Bausch Health US, LLC | $42.50 | 2019 | |
| Alfasigma USA, INC. | $31.52 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Salmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.